Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (Umbriel)
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids
- Asthma
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- AstraZeneca
- Enrolment target
- 540
- Started
- 26 March 2025
- Main results due (estimated)
- 7 June 2027
- Study ends (estimated)
- 28 February 2028
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Sites
- 223 · 10 in India
- First posted
- 17 April 2025
- Registry updated
- 30 October 2026
This is a parallel-group treatment study with 3 arms. Participants will be randomised in a ratio of 1:1:1 to one of the 3 treatment arms.
Can you take part?
- Ages 18 years to 75 years.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Provision of signed and dated written informed consent prior to any study-specific procedures. 2. Adults aged 18-75, inclusive when signing the informed consent. 3. Documented physician-diagnosis of asthma for at least 12 months. 4. Treated with medium or high dose ICS in combination with LABA. 5. Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 . 6. Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal. 7. Documented exacerbation history in the last 12 months and biomarker requirements of: 1. ≥ 2 severe exacerbations OR 2. 1 severe exacerbation and: (i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb 8. Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary. 9. Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test. 10. Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: 1. Completed treatment for respiratory infection with antibiotics in the 4 weeks prior to Visit 1. 2. Clinically significant pulmonary disease other than asthma . 3. Current smokers, former smokers with \>10 pack-years history. 4. Clinically significant aortic stenosis or pulmonary arterial hypertension. 5. Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immune complex disease. 6. Unstable cardiovascular disorders.
What this study is about
In the sponsor’s own words, from the registry.
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
What participants receive
- Experimental
Tozorakimab Dose 1
Dosing subcutaneously tozorakimab Dose 1
Drug: Tozorakimab
- Experimental
Tozorakimab Dose 2
Dosing subcutaneously tozorakimab Dose 2 and placebo
Drug: Tozorakimab
- Placebo comparator
Placebo
Dosing subcutaneously with equivalent volume to tozorakimab
Drug: Placebo
Interventions
TozorakimabDrug
The drug will be administered subcutaneously.
PlaceboDrug
Placebo will be administered subcutaneously.
What the study measures
Primary outcomes
Annualised rate of severe asthma exacerbations
The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and ≥ 1 severe exacerbation within 12 months prior to screening.
Time frame: Over 26 to 52 weeks
Secondary outcomes
Annualised rate of severe asthma exacerbations
The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and baseline eosinophils \< 300 cells/µL and history of ≥2 severe exacerbations within 12 months prior to screening.
Time frame: Over 26 to 52 weeks
Time to first severe asthma exacerbation
To evaluate the effect of two dose levels of tozorakimab compared to placebo on time to first severe asthma exacerbations.
Time frame: Over 26 to 52 weeks
Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1)
Difference in mean change from baseline between tozorakimab and placebo.
Time frame: Over weeks 20 to 26
Change from baseline in post-bronchodilator FEV1
Difference in mean change from baseline between tozorakimab and placebo.
Time frame: At week 26
Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6)
Difference in mean change from baseline between tozorakimab and placebo. The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease.
Time frame: At week 26
Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ12+)
Difference in mean change from baseline between tozorakimab and placebo. The AQLQ12+ includes 32 questions grouped into four domains: symptoms; activity limitations; emotional function; and, environmental stimuli. Each question is scored on a seven-point Likert scale, which ranges from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean of all questions, and the four domain scores are the means of the scores for the questions in the respective domains.
Time frame: At week 26
Trough serum concentrations of tozorakimab
Pharmacokinetics: concentrations of tozorakimab in trough serum.
Time frame: Over 52 weeks
Anti-drug antibody incidence
Immunogenicity: Number of Participants With Positive Antibodies to tozorakimab
Time frame: Over 52 weeks
Who is running it
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- AstraZeneca
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- D9181C00002
- Other IDs
- 2024-519116-14-00
Study sites(223)
Research Site
Belagavi, India
Recruiting
Research Site
Coimbatore, India
Recruiting
Research Site
Dehradun, India
Recruiting
Research Site
Delhi, India
Recruiting
Research Site
New Delhi, India
Recruiting
Research Site
Vadodara, India
Recruiting
Research Site
Lucknow, India
Suspended
Research Site
Faridabad, India
Withdrawn
Research Site
Gūrgaon, India
Withdrawn
Research Site
Kochi, India
Terminated
Research Site
Bakersfield, California, United States
Recruiting
Research Site
Long Beach, California, United States
Recruiting
Research Site
Newport Beach, California, United States
Recruiting
Research Site
San Jose, California, United States
Recruiting
Research Site
Noblesville, Indiana, United States
Recruiting
Research Site
Hutchinson, Kansas, United States
Recruiting
Research Site
Louisville, Kentucky, United States
Recruiting
Research Site
Worcester, Massachusetts, United States
Recruiting
Research Site
Farmington Hills, Michigan, United States
Recruiting
Research Site
Grand Island, Nebraska, United States
Recruiting
Research Site
Omaha, Nebraska, United States
Recruiting
Research Site
Mullica Hill, New Jersey, United States
Recruiting
Research Site
Toms River, New Jersey, United States
Recruiting
Research Site
Horseheads, New York, United States
Recruiting
Research Site
Maspeth, New York, United States
Recruiting
Research Site
Kings Mountain, North Carolina, United States
Recruiting
Research Site
Toledo, Ohio, United States
Recruiting
Research Site
Medford, Oregon, United States
Recruiting
Research Site
Portland, Oregon, United States
Recruiting
Research Site
Philadelphia, Pennsylvania, United States
Recruiting
Research Site
Smithfield, Pennsylvania, United States
Recruiting
Research Site
Rock Hill, South Carolina, United States
Recruiting
Research Site
Austin, Texas, United States
Recruiting
Research Site
Boerne, Texas, United States
Recruiting
Research Site
Dallas, Texas, United States
Recruiting
Research Site
El Paso, Texas, United States
Recruiting
Research Site
Greenville, Texas, United States
Recruiting
Research Site
Kingwood, Texas, United States
Recruiting
Research Site
Sugar Land, Texas, United States
Recruiting
Research Site
Victoria, Texas, United States
Recruiting
Showing 40 of 223 sites. 144 recruiting, 39 not recruiting and 40 cancelled; 10 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
- What is shared
- Study protocol, Sap
- When
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
- Where
- https://vivli.org/
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Source: ClinicalTrials.gov record NCT06932263, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.